1. RockeyDC, BellPD, HillJA. Fibrosis: a common pathway of organ injury and failure. NEJM2015;372:1138. CrossRef

2. SchuppanD, RuehlM, SomasundaramR, et al.Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis2001;21:351. CrossRef

3. JarnaginWR, RockeyDC, KotelianskyVE, et al.Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol1994;127:2037. CrossRef

4. BedossaP, FerlicotS, ParadisV, et al.Dystroglycan expression in hepatic stellate cells: role in liver fibrosis. Lab Invest2002;82:1053. CrossRef

5. ArthurMJ, FibrogenesisII. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol2000;279:G245.

6. IredaleJP. Stellate cell behavior during resolution of liver injury. Semin Liver Dis2001;21:427. CrossRef

7. FriedmanSL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev2008;88:125. CrossRef

8. MaherJJ, McGuireRF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest1990;86:1641. CrossRef

9. RockeyDC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis2006;10:459, vii‐viii. CrossRef

10. LiZ, DranoffJA, ChanEP, et al.Transforming growth factor‐beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology2007;46:1246. CrossRef

11. KisselevaT, UchinamiH, FeirtN, et al.Bone marrow‐derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol2006;45:429. CrossRef

12. KalluriR, NeilsonEG. Epithelial‐mesenchymal transition and its implications for fibrosis. J Clin Invest2003;112:1776. CrossRef

13. KaimoriA, PotterJ, KaimoriJY, et al.Transforming growth factor‐beta1 induces an epithelial‐to‐mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem2007;282:22089. CrossRef

14. WakeK. Perisinusoidal stellate cells (fat‐storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A‐storing cells in extrahepatic organs. Int Rev Cytol1980;66:303. CrossRef

15. BlomhoffR, WakeK. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J1991;5:271.

16. SchuppanD. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis1990;10:1. CrossRef

17. RockeyDC, BoylesJK, GabbianiG, et al.Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol1992;24:193.

18. HinzB. Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol2006;85:175. CrossRef

19. GabbianiG. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol2003;200:500. CrossRef

20. WakeK, SatoT. Intralobular heterogeneity of perisinusoidal stellate cells in porcine liver. Cell Tissue Res1993;273:227. CrossRef

21. PoliG. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med2000;21:49. CrossRef

22. UrtasunR, LopategiA, GeorgeJ, et al.Osteopontin, an oxidant stress sensitive cytokine, up‐regulates collagen‐I via integrin alpha(V)beta(3) engagement and PI3K/pAkt/NFkappaB signaling. Hepatology2012;55:594. CrossRef

23. MormoneE, LuY, GeX, et al.Fibromodulin, an oxidative stress‐sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. Gastroenterology2012;142:612. CrossRef

24. SanchoP, MainezJ, Crosas‐MolistE, et al.NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS ONE2012;7:e45285. CrossRef

25. DunningS, Ur RehmanA, TieboschMH, et al.Glutathione and antioxidant enzymes serve complementary roles in protecting activated hepatic stellate cells against hydrogen peroxide‐induced cell death. Biochim Biophys Acta2013;1832:2027. CrossRef

26. JiangJX, TorokNJ. Liver Injury and the Activation of the Hepatic Myofibroblasts. Curr Pathobiol Rep2013;1:215. CrossRef

27. CuiW, MatsunoK, IwataK, et al.NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology2011;54:949. CrossRef

28. PellicoroA, RamachandranP, IredaleJP, et al.Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol2014;14:181. CrossRef

29. PresserLD, McRaeS, WarisG. Activation of TGF‐beta1 promoter by hepatitis C virus‐induced AP‐1 and Sp1: role of TGF‐beta1 in hepatic stellate cell activation and invasion. PLoS ONE2013;8:e56367. CrossRef

30. SekiE, De MinicisS, OsterreicherCH, et al.TLR4 enhances TGF‐beta signaling and hepatic fibrosis. Nat Med2007;13:1324. CrossRef

31. GuoJ, LokeJ, ZhengF, et al.Functional linkage of cirrhosis‐predictive single nucleotide polymorphisms of Toll‐like receptor 4 to hepatic stellate cell responses. Hepatology2009;49:960. CrossRef

32. CanbayA, TaimrP, TorokN, et al.Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest2003;83:655. CrossRef

33. LeeTF, LinYL, HuangYT. Kaerophyllin inhibits hepatic stellate cell activation by apoptotic bodies from hepatocytes. Liver Int2011;31:618. CrossRef

34. CanbayA, HiguchiH, BronkSF, et al.Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology2002;123:1323. CrossRef

35. SchnablB, PurbeckCA, ChoiYH, et al.Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology2003;37:653. CrossRef

36. KrizhanovskyV, YonM, DickinsRA, et al.Senescence of activated stellate cells limits liver fibrosis. Cell2008;134:657. CrossRef

37. KongX, FengD, WangH, et al.Interleukin‐22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology2012;56:1150. CrossRef

38. DeleveLD, WangX, GuoY. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology2008;48:920. CrossRef

39. LeCouterJ, MoritzDR, LiB, et al.Angiogenesis‐independent endothelial protection of liver: role of VEGFR‐1. Science2003;299:890. CrossRef

40. OlasoE, SaladoC, EgilegorE, et al.Proangiogenic role of tumor‐activated hepatic stellate cells in experimental melanoma metastasis. Hepatology2003;37:674. CrossRef

41. YoshijiH, KuriyamaS, YoshiiJ, et al.Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut2003;52:1347. CrossRef

42. MannJ, MannDA. Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev2009;61:497. CrossRef

43. De MinicisS, SekiE, UchinamiH, et al.Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology2007;132:1937. CrossRef

44. FriedmanSL. Transcriptional regulation of stellate cell activation. J Gastroenterol Hepatol2006;21(Suppl 3):S79. CrossRef

45. MarraF, EfsenE, RomanelliRG, et al.Ligands of peroxisome proliferator‐activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology2000;119:466. CrossRef

46. MiyaharaT, SchrumL, RippeR, et al.Peroxisome proliferator‐activated receptors and hepatic stellate cell activation. J Biol Chem2000;275:35715. CrossRef

47. YangL, ChanCC, KwonOS, et al.Regulation of peroxisome proliferator‐activated receptor‐gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol2006;291:G902. CrossRef

48. FiorucciS, AntonelliE, RizzoG, et al.The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology2004;127:1497. CrossRef

49. HellemansK, VerbuystP, QuartierE, et al.Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology2004;39:97. CrossRef

50. BeavenSW, WroblewskiK, WangJ, et al.Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology2011;140:1052. CrossRef

51. PaikYH, SchwabeRF, BatallerR, et al.Toll‐like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology2003;37:1043. CrossRef

52. RippeRA, SchrumLW, StefanovicB, et al.NF‐kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol1999;18:751. CrossRef

53. SmartDE, GreenK, OakleyF, et al.JunD is a profibrogenic transcription factor regulated by Jun N‐terminal kinase‐independent phosphorylation. Hepatology2006;44:1432. CrossRef

54. Ghiassi‐NejadZ, Hernandez‐GeaV, WoodrellC, et al.Reduced hepatic stellate cell expression of Kruppel‐like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology2013;57:786. CrossRef

55. ShiZ, RockeyDC. Interferon‐gamma‐mediated inhibition of serum response factor‐dependent smooth muscle‐specific gene expression. J Biol Chem2010;285:32415. CrossRef

56. WeiskirchenR, MoserM, WeiskirchenS, et al.LIM‐domain protein cysteine‐ and glycine‐rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J2001;359:485. CrossRef

57. KalinichenkoVV, BhattacharyyaD, ZhouY, et al.Foxf1 +/− mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology2003;37:107. CrossRef

58. ThumT, GrossC, FiedlerJ, et al.MicroRNA‐21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature2008;456:980. CrossRef

59. LiuG, FriggeriA, YangY, et al.miR‐21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med2010;207:1589. CrossRef

60. ChauBN, XinC, HartnerJ, et al.MicroRNA‐21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med2012;4:121ra18.

61. RoderburgC, UrbanGW, BettermannK, et al.Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis. Hepatology2010.

62. LiJ, GhazwaniM, ZhangY, et al.miR‐122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol2013;58:522. CrossRef

63. SunX, HeY, MaTT, et al.Participation of miR‐200a in TGF‐beta1‐mediated hepatic stellate cell activation. Mol Cell Biochem2014;388:11. CrossRef

64. RoderburgC, LueddeM, Vargas CardenasD, et al.miR‐133a mediates TGF‐beta‐dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol2013;58:736. CrossRef

65. HeY, HuangC, ZhangSP, et al.The potential of microRNAs in liver fibrosis. Cell Signal2012;24:2268. CrossRef

66. WellsRG. Fibrogenesis. V. TGF‐beta signaling pathways. Am J Physiol Gastrointest Liver Physiol2000;279:G845.

67. GressnerAM, WeiskirchenR, BreitkopfK, et al.Roles of tgf‐Beta in hepatic fibrosis. Front Biosci2002;7:D793. CrossRef

68. BatallerR, BrennerDA. Liver fibrosis. J Clin Invest2005;115:209. CrossRef

69. RockeyDC. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol2013;11:224. CrossRef

70. PinzaniM. PDGF and signal transduction in hepatic stellate cells. Front Biosci2002;7:d1720. CrossRef

71. RockeyDC, FouassierL, ChungJJ, et al.Cellular localization of endothelin‐1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology1998;27:472. CrossRef

72. PinzaniM, MilaniS, De FrancoR, et al.Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology1996;110:534. CrossRef

73. MarraF, GrandalianoG, ValenteAJ, et al.Thrombin stimulates proliferation of liver fat‐storing cells and expression of monocyte chemotactic protein‐1: potential role in liver injury. Hepatology1995;22:780.

74. RosenbaumJ, BlazejewskiS, PreauxAM, et al.Fibroblast growth factor 2 and transforming growth factor beta 1 interactions in human liver myofibroblasts. Gastroenterology1995;109:1986. CrossRef

75. PinzaniM, AbboudHE, AronDC. Secretion of insulin‐like growth factor‐I and binding proteins by rat liver fat‐storing cells: regulatory role of platelet‐derived growth factor. Endocrinology1990;127:2343. CrossRef

76. MolesA, TarratsN, Fernandez‐ChecaJC, et al.Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology2009;49:1297. CrossRef

77. YangL, StimpsonSA, ChenL, et al.Effectiveness of the PPARgamma agonist, GW570, in liver fibrosis. Inflamm Res2010;59:1061. CrossRef

78. SunWY, SongY, HuSS, et al.Depletion of beta‐arrestin2 in hepatic stellate cells reduces cell proliferation via ERK pathway. J Cell Biochem2013;114:1153. CrossRef

79. RockeyDC, HoussetCN, FriedmanSL. Activation‐dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest1993;92:1795. CrossRef

80. RockeyDC. Vascular mediators in the injured liver. Hepatology2003;37:4. CrossRef

81. HoussetC, RockeyDC, BissellDM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci U S A1993;90:9266. CrossRef

82. RockeyDC, ChungJJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest1995;95:1199. CrossRef

83. RockeyDC, WeymouthN, ShiZ. Smooth muscle alpha actin (Acta2) and myofibroblast function during hepatic wound healing. PLoS ONE2013;8:e77166. CrossRef

84. MeltonAC, SoonRKJr, ParkJG, et al.Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis. Am J Physiol Gastrointest Liver Physiol2007;293:G1272. CrossRef

85. MarraF. Chemokines in liver inflammation and fibrosis. Front Biosci2002;7:d1899. CrossRef

86. OhataM, YamauchiM, TakedaK, et al.RAR and RXR expression by Kupffer cells. Exp Mol Pathol2000;68:13. CrossRef

87. SchwabeRF, BatallerR, BrennerDA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol2003;285:G949. CrossRef

88. GacaMD, ZhouX, BenyonRC. Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase‐activated receptors. J Hepatol2002;36:362. CrossRef

89. BatallerR, PaikYH, LindquistJN, et al.Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology2004;126:529. CrossRef

90. EfsenE, GrapponeC, DeFrancoRM, et al.Up‐regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol2002;37:39. CrossRef

91. KobayashiS, SekiS, KawadaN, et al.Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast‐like cells. Cell Tissue Res2003;311:353.

92. ShiZ, WakilAE, RockeyDC. Strain‐specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A1997;94:10663. CrossRef

93. SafadiR, OhtaM, AlvarezCE, et al.Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin‐10 from hepatocytes. Gastroenterology2004;127:870. CrossRef

94. GaoB, RadaevaS, JeongWI. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol2007;1:173. CrossRef

95. HoltAP, HaughtonEL, LalorPF, et al.Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology2009;136:705. CrossRef

96. ZhanS, ChanCC, SerdarB, et al.Fibronectin stimulates endothelin‐1 synthesis in rat hepatic myofibroblasts via a Src/ERK‐regulated signaling pathway. Gastroenterology2009;136:2345. CrossRef

97. TsukamotoH. Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal2002;4:741. CrossRef

98. MuroAF, MorettiFA, MooreBB, et al.An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med2008;177:638. CrossRef

99. BorderWA, NobleNA, YamamotoT, et al.Natural inhibitor of transforming growth factor‐beta protects against scarring in experimental kidney disease. Nature1992;360:361. CrossRef

100. VogelW, GishGD, AlvesF, et al.The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell1997;1:13. CrossRef

101. IkedaK, WangLH, TorresR, et al.Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem2002;277:19206. CrossRef

102. OlasoE, IkedaK, EngFJ, et al.DDR2 receptor promotes MMP‐2‐mediated proliferation and invasion by hepatic stellate cells. J Clin Invest2001;108:1369. CrossRef

103. LuoZ, LiuH, SunX, et al.RNA interference against discoidin domain receptor 2 ameliorates alcoholic liver disease in rats. PLoS ONE2013;8:e55860. CrossRef

104. Racine‐SamsonL, RockeyDC, BissellDM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem1997;272:30911. CrossRef

105. LevineD, RockeyDC, MilnerTA, et al.Expression of the integrin alpha8beta1 during pulmonary and hepatic fibrosis. Am J Pathol2000;156:1927. CrossRef

106. GaoR, BrigstockDR. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C‐terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem2004;279:8848. CrossRef

107. ZhouX, MurphyFR, GehduN, et al.Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem2004;279:23996. CrossRef

108. HendersonNC, ArnoldTD, KatamuraY, et al.Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med2013;19:1617. CrossRef

109. ShafieiMS, RockeyDC. The role of integrin‐linked kinase in liver wound healing. J Biol Chem2006;281:24863. CrossRef

110. ShafieiMS, RockeyDC. The function of integrin‐linked kinase in normal and activated stellate cells: implications for fibrogenesis in wound healing. Lab Invest2012;92:305. CrossRef

111. GacaMD, PickeringJA, ArthurMJ, et al.Human and rat hepatic stellate cells produce stem cell factor: a possible mechanism for mast cell recruitment in liver fibrosis. J Hepatol1999;30:850. CrossRef

112. PinzaniM, MarraF. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis2001;21:397. CrossRef

113. SaimanY, AgarwalR, HickmanDA, et al.CXCL12 induces hepatic stellate cell contraction through a calcium independent pathway. Am J Physiol Gastrointest Liver Physiol2013.

114. IredaleJP, BenyonRC, PickeringJ, et al.Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest1998;102:538. CrossRef

115. SoharaN, ZnoykoI, LevyMT, et al.Reversal of activation of human myofibroblast‐like cells by culture on a basement membrane‐like substrate. J Hepatol2002;37:214. CrossRef

116. PreauxAM, D'OrthoMP, BraletMP, et al.Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase‐2. Hepatology2002;36:615. CrossRef

117. LiL, TaoJ, DavailleJ, et al.15‐deoxy‐Delta 12,14‐prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome‐proliferator‐activated receptors. J Biol Chem2001;276:38152.

118. ThoenLF, GuimaraesEL, GrunsvenLA. Autophagy: a new player in hepatic stellate cell activation. Autophagy2012;8:126. CrossRef

119. ThoenLF, GuimaraesEL, DolleL, et al.A role for autophagy during hepatic stellate cell activation. J Hepatol2011;55:1353. CrossRef

120. Hernndez‐GeaV, FriedmanSL. Autophagy fuels tissue fibrogenesis. Autophagy2012;8:849. CrossRef

121. Hernandez‐GeaV, Ghiassi‐NejadZ, RozenfeldR, et al.Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology2012;142:938. CrossRef

122. LozanoR, NaghaviM, ForemanK, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380:2095. CrossRef

123. MurrayCJ, LopezAD. Measuring the global burden of disease. N Engl J Med2013;369:448. CrossRef

124. RehmJ, SamokhvalovAV, ShieldKD. Global burden of alcoholic liver diseases. J Hepatol2013;59:160. CrossRef

125. NeffGW, DuncanCW, SchiffER. The current economic burden of cirrhosis. Gastroenterol Hepatol2011;7:661.

126. El‐SeragHB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology2012;142:1264. CrossRef

127. PoynardT, MathurinP, LaiCL, et al.A comparison of fibrosis progression in chronic liver diseases. J Hepatol2003;38:257. CrossRef

128. PoynardT, BedossaP, OpolonP. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet1997;349:825. CrossRef

129. TheinHH, YiQ, DoreGJ, et al.Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression. Hepatology2008;48:418. CrossRef

130. HuangH, ShiffmanML, FriedmanS, et al.A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology2007;46:297. CrossRef

131. KonermanMA, MehtaSH, SutcliffeCG, et al.Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology2013.

132. YilmazN, ShiffmanML, StravitzRT, et al.A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl2007;13:975. CrossRef

133. BerenguerM, SchuppanD. Progression of liver fibrosis in post‐transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol2013;58:1028. CrossRef

134. HillebrandtS, WasmuthHE, WeiskirchenR, et al.Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet2005;37:835. CrossRef

135. HillebrandtS, GoosC, MaternS, et al.Genome‐wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology2002;123:2041. CrossRef

136. PattonHM, PatelK, BehlingC, et al.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol2004;40:484. CrossRef

137. FartouxL, Poujol‐RobertA, GuechotJ, et al.Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut2005;54:1003. CrossRef

138. PerumalswamiP, KleinerDE, LutchmanG, et al.Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology2006;43:780. CrossRef

139. HsuYS, ChienRN, YehCT, et al.Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology2002;35:1522. CrossRef

140. LindhM, HoralP, DhillonAP, et al.Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat2000;7:258. CrossRef

141. MericanI, GuanR, AmarapukaD, et al.Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol2000;15:1356. CrossRef

142. IloejeUH, YangHI, SuJ, et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology2006;130:678. CrossRef

143. KobayashiM, AraseY, IkedaK, et al.Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol2002;37:35. CrossRef

144. HadziyannisSJ, TassopoulosNC, HeathcoteEJ, et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen‐negative chronic hepatitis B. N Engl J Med2003;348:800. CrossRef

145. FarciP, RoskamsT, ChessaL, et al.Long‐term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology2004;126:1740. CrossRef

146. LiawYF, SungJJ, ChowWC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med2004;351:1521. CrossRef

147. LeeMH, YangHI, LiuJ, et al.Prediction models of long‐term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology2013;58:546. CrossRef

148. RaynardB, BalianA, FallikD, et al.Risk factors of fibrosis in alcohol‐induced liver disease. Hepatology2002;35:635. CrossRef

149. TianC, StokowskiRP, KershenobichD, et al.Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet2010;42:21. CrossRef

150. Falck‐YtterY, YounossiZM, MarchesiniG, et al.Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis2001;21:17. CrossRef

151. Dam‐LarsenS, BeckerU, FranzmannMB, et al.Final results of a long‐term, clinical follow‐up in fatty liver patients. Scand J Gastroenterol2009;44:1236. CrossRef

152. ArgoCK, NorthupPG, Al‐OsaimiAM, et al.Systematic review of risk factors for fibrosis progression in non‐alcoholic steatohepatitis. J Hepatol2009;51:371. CrossRef

153. CaldwellS, ArgoC. The natural history of non‐alcoholic fatty liver disease. Dig Dis2010;28:162. CrossRef

154. SobeskyR, MathurinP, CharlotteF, et al.Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology1999;116:378. CrossRef

155. PoynardT, RatziuV, CharlotteF, et al.Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol2001;34:730. CrossRef

156. RockeyDC, BissellDM. Noninvasive measures of liver fibrosis. Hepatology2006;43:S113. CrossRef

157. ChalasaniN, ImperialeTF, IsmailA, et al.Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol1999;94:3285. CrossRef

158. GianniniE, RissoD, BottaF, et al.Validity and clinical utility of the aspartate aminotransferase‐alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus‐related chronic liver disease. Arch Intern Med2003;163:218. CrossRef

159. ShethSG, FlammSL, GordonFD, et al.AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol1998;93:44. CrossRef

160. GianniniE, TestaR. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple. Hepatology2003;38:1312, author reply 3. CrossRef

161. FornsX, AmpurdanesS, LlovetJM, et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology2002;36:986. CrossRef

162. WaiCT, GreensonJK, FontanaRJ, et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology2003;38:518.

163. PoynardT, Imbert‐BismutF, MunteanuM, et al.Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol2004;3:8. CrossRef

164. PatelK, GordonSC, JacobsonI, et al.Evaluation of a panel of non‐invasive serum markers to differentiate mild from moderate‐to‐advanced liver fibrosis in chronic hepatitis C patients. J Hepatol2004;41:935. CrossRef

165. RosenbergWM, VoelkerM, ThielR, et al.Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology2004;127:1704. CrossRef

166. ParkesJ, RoderickP, HarrisS, et al.Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut2010;59:1245. CrossRef

167. DevA, WhiteI, SymondsW, et al.Serum proteomic analysis in hepatitis C patients with and without fibrosis. J Hepatol2005.

168. CallewaertN, Van VlierbergheH, Van HeckeA, et al.Noninvasive diagnosis of liver cirrhosis using DNA sequencer‐based total serum protein glycomics. Nat Med2004;10:429. CrossRef

169. WellsRG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol2005;39:S158. CrossRef

170. HinzB. Tissue stiffness, latent TGF‐beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep2009;11:120. CrossRef

171. RockeyDC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology2008;134:8. CrossRef

172. BeljaarsL, MeijerDK, PoelstraK. Targeting hepatic stellate cells for cell‐specific treatment of liver fibrosis. Front Biosci2002;7:e214. CrossRef

173. GianniniEG, FasoliA, BorroP, et al.13C‐galactose breath test and 13C‐aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol2005;3:279. CrossRef

174. TestaR, CaglierisS, RissoD, et al.Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol1997;92:2268.

175. RockeyDC, CaldwellSH, GoodmanZD, et al.Liver biopsy. Hepatology2009;49:1017. CrossRef

176. RegevA, BerhoM, JeffersLJ, et al.Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol2002;97:2614. CrossRef

177. RatziuV, CharlotteF, HeurtierA, et al.Sampling variability of liver biopsy in nonalcoholic Fatty liver disease. Gastroenterology2005;128:1898. CrossRef

178. D'AmicoG, Garcia‐TsaoG, PagliaroL. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol2006;44:217. CrossRef

179. PughRN, Murray‐LyonIM, DawsonJL, et al.Transection of the oesophagus for bleeding oesophageal varices. Br J Surg1973;60:646. CrossRef

180. WiesnerRH, McDiarmidSV, KamathPS, et al.MELD and PELD: application of survival models to liver allocation. Liver Transpl2001;7:567. CrossRef

181. KamathPS, WiesnerRH, MalinchocM, et al.A model to predict survival in patients with end‐stage liver disease. Hepatology2001;33:464. CrossRef

182. RipollC, GroszmannR, Garcia‐TsaoG, et al.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology2007;133:481. CrossRef

183. RipollC, LastraP, RinconD, et al.Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scand J Gastroenterol2012;47:204. CrossRef

184. DurandF, VallaD. Assessment of prognosis of cirrhosis. Semin Liver Dis2008;28:110. CrossRef

185. FattovichG, GiustinaG, DegosF, et al.Morbidity and mortality in compensated cirrhosis type C: a retrospective follow‐up study of 384 patients. Gastroenterology1997;112:463. CrossRef

186. LylesT, ElliottA, RockeyDC. A risk scoring system to predict in‐hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol2014;48:712. CrossRef

187. RockeyDC. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol2005;3:95. CrossRef

188. RockeyDC, ChungJJ. Endothelin antagonism in experimental hepatic fibrosis. implications for endothelin in the pathogenesis of wound healing. J Clin Invest1996;98:1381. CrossRef

189. EllisEL, MannDA. Clinical evidence for the regression of liver fibrosis. J Hepatol2012;56:1171. CrossRef

190. Crespo‐LeiroMG, RoblesO, PaniaguaMJ, et al.Reversal of cardiac cirrhosis following orthotopic heart transplantation. Am J Transplant2008;8:1336. CrossRef

191. CzajaAJ, CarpenterHA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol2004;40:646. CrossRef

192. El‐HusseiniR, KaplanMM. Reversal of portal hypertension in a patient with primary biliary cirrhosis: disappearance of esophageal varices and thrombocytopenia. Am J Gastroenterol2004;99:1859. CrossRef

193. HammelP, CouvelardA, O'TooleD, et al.Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med2001;344:418. CrossRef

194. WanlessIR, NakashimaE, ShermanM. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med2000;124:1599.

195. DufourJF, DeLellisR, KaplanMM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med1997;127:981. CrossRef

196. KweonYO, GoodmanZD, DienstagJL, et al.Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol2001;35:749. CrossRef

197. ChangTT, LiawYF, WuSS, et al.Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology2010;52:866. CrossRef

198. MarcellinP, GaneE, ButiM, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5‐year open‐label follow‐up study. Lancet2013;381:468. CrossRef

199. LiawYF. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J Hepatol2013;59:880. CrossRef

200. ShiratoriY, ImazekiF, MoriyamaM, et al.Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med2000;132:517. CrossRef

201. PoynardT, McHutchisonJ, MannsM, et al.Impact of pegylated interferon alfa‐2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology2002;122:1303. CrossRef

202. MalletV, GilgenkrantzH, SerpaggiJ, et al.Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med2008;149:399. CrossRef

203. PowellLW, KerrJF. Reversal of "cirrhosis" in idiopathic haemochromatosis following long‐term intensive venesection therapy. Australas Ann Med1970;19:54.

204. BlumbergRS, ChopraS, IbrahimR, et al.Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology1988;95:1399.

205. SorensenTI, OrholmM, BentsenKD, et al.Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet1984;2:241. CrossRef

206. BerheN, MyrvangB, GundersenSG. Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty‐six month follow‐up study in Ethiopia. Am J Trop Med Hyg2008;78:228.

207. OzaslanE. Drug‐induced autoimmune hepatitis: an easily reversible type of liver fibrosis?Hepatology2011;53:370. CrossRef

208. CarrionJA, NavasaM, Garcia‐RetortilloM, et al.Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology2007;132:1746. CrossRef

209. RobertsS, GordonA, McLeanC, et al.Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C‐related cirrhosis. Clin Gastroenterol Hepatol2007;5:932. CrossRef

210. CzajaAJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther2013;38:343. CrossRef

211. CzajaAJ. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther2014;39:385. CrossRef

212. RamondMJ, PoynardT, RueffB, et al.A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med1992;326:507. CrossRef

213. SpahrL, Rubbia‐BrandtL, PuginJ, et al.Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule‐1 in hepatic venous blood. J Hepatol2001;35:582. CrossRef

214. RambaldiA, SaconatoHH, ChristensenE, et al.Systematic review: glucocorticosteroids for alcoholic hepatitis – a Cochrane Hepato‐Biliary Group systematic review with meta‐analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther2008;27:1167. CrossRef

215. CohenSM, AhnJ. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther2009;30:3. CrossRef

216. NelsonDR, TuZ, Soldevila‐PicoC, et al.Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect. Hepatology2003;38:859. CrossRef

217. TilgH, JalanR, KaserA, et al.Anti‐tumor necrosis factor‐alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol2003;38:419. CrossRef

218. BoetticherNC, PeineCJ, KwoP, et al.A randomized, double‐blinded, placebo‐controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology2008;135:1953. CrossRef

219. ParkerR, ArmstrongMJ, CorbettC, et al.Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther2013;37:845. CrossRef

220. SchaffZ, LapisK, SzendeB, et al.The effect of D‐penicillamine on CCl4‐induced experimental liver cirrhosis. Exp Pathol1991;43:111. CrossRef

221. BodenheimerHCJr, SchaffnerF, SternliebI, et al.A prospective clinical trial of D‐penicillamine in the treatment of primary biliary cirrhosis. Hepatology1985;5:1139. CrossRef

222. DicksonER, FlemingTR, WiesnerRH, et al.Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med1985;312:1011. CrossRef

223. AithalGP, HaugkB, DasS, et al.Monitoring methotrexate‐induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?Aliment Pharmacol Ther2004;19:391. CrossRef

224. HendrickseMT, RigneyE, GiafferMH, et al.Low‐dose methotrexate is ineffective in primary biliary cirrhosis: long‐term results of a placebo‐controlled trial [see comments]. Gastroenterology1999;117:400. CrossRef

225. BachN, BodianC, BodenheimerH, et al.Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol2003;98:187. CrossRef

226. LieberCS, WeissDG, GroszmannR, et al.Veterans affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res2003;27:1765. CrossRef

227. JiaJD, BauerM, ChoJJ, et al.Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP‐1. J Hepatol2001;35:392. CrossRef

228. LieberCS, LeoMA, CaoQ, et al.Silymarin retards the progression of alcohol‐induced hepatic fibrosis in baboons. J Clin Gastroenterol2003;37:336. CrossRef

229. RambaldiA, JacobsBP, IaquintoG, et al.Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic cochrane hepato‐biliary group review with meta‐analyses of randomized clinical trials. Am J Gastroenterol2005;100:2583. CrossRef

230. BrownKE, PoulosJE, LiL, et al.Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol1997;272:G116.

231. HouglumK, VenkataramaniA, LycheK, et al.A pilot study of the effects of d‐alpha‐tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology1997;113:1069. CrossRef

232. HasegawaT, YonedaM, NakamuraK, et al.Plasma transforming growth factor‐beta1 level and efficacy of alpha‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther2001;15:1667. CrossRef

233. MezeyE, PotterJ, Rennie‐TankersleyL, et al.A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. J Hepatol2004;40:40. CrossRef

234. StewartS, PrinceM, BassendineM, et al.A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol2002;36(S):16. CrossRef

235. SanyalAJ, ChalasaniN, KowdleyKV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med2010;362:1675. CrossRef

236. SongBJ, RockeyDC. Status of research on vitamin D supplementation in treating or preventing liver fibrosis. Liver Int2013;33:653. CrossRef

237. HarrisonSA, TorgersonS, HayashiP, et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol2003;98:2485. CrossRef

238. AhmadA, AfrozN, GuptaUD, et al.Vitamin B supplement alleviates N′‐nitrosodimethylamine‐induced hepatic fibrosis in rats. Pharm Biol2014; PMID:24405044.

239. SakaidaI, TsuchiyaM, KawaguchiK, et al.Herbal medicine Inchin‐ko‐to (TJ‐135) prevents liver fibrosis and enzyme‐altered lesions in rat liver cirrhosis induced by a choline‐deficient L‐amino acid‐defined diet. J Hepatol2003;38:762. CrossRef

240. ShimizuI, MaYR, MizobuchiY, et al.Effects of Sho‐saiko‐to, a Japanese herbal medicine, on hepatic fibrosis in rats [see comments]. Hepatology1999;29:149. CrossRef

241. ZhangXL, LiuL, JiangHQ. Salvia miltiorrhiza monomer IH764‐3 induces hepatic stellate cell apoptosis via caspase‐3 activation. World J Gastroenterol2002;8:515.

242. ChenZX, ZhangSJ, LaoSX, et al.He Jie Tang in the treatment of chronic hepatitis B patients. World J Gastroenterol2005;11:6638. CrossRef

243. WangBE. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol2000;15(Suppl):E67. CrossRef

244. NavarroVJ, SeeffLB. Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis2013;17:715, x. CrossRef

245. LuSC, TsukamotoH, MatoJM. Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol2002;27:155. CrossRef

246. Anonymous. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol1993;17:227. CrossRef

247. KaplanMM, DeLellisRA, WolfeHJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med1997;126:682. CrossRef

248. KaplanMM, ChengS, PriceLL, et al.A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten‐year results. Hepatology2004;39:915. CrossRef

249. MatoJM, CamaraJ, Fernandez de PazJ, et al.S‐adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo‐controlled, double‐blind, multicenter clinical trial. J Hepatol1999;30:1081. CrossRef

250. RambaldiA, GluudC. Meta‐analysis of propylthiouracil for alcoholic liver disease – a Cochrane Hepato‐Biliary Group Review. Liver2001;21:398. CrossRef

251. Nava‐OcampoAA, SusterS, MurielP. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest1997;27:77. CrossRef

252. StiehlA. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann Med1994;26:345. CrossRef

253. CombesB, CarithersRLJr, MaddreyWC, et al.A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology1995;22:759.

254. JacqueminE, HermansD, MyaraA, et al.Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology1997;25:519. CrossRef

255. LindbladA, GlaumannH, StrandvikB. A two‐year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis‐associated liver disease. Hepatology1998;27:166. CrossRef

256. GoulisJ, LeandroG, BurroughsAK. Randomised controlled trials of ursodeoxycholic‐acid therapy for primary biliary cirrhosis: a meta‐analysis. Lancet1999;354:1053. CrossRef

257. PouponRE, BonnandAM, ChretienY, et al.Ten‐year survival in ursodeoxycholic acid‐treated patients with primary biliary cirrhosis. The UDCA‐PBC Study Group. Hepatology1999;29:1668. CrossRef

258. DegottC, ZafraniES, CallardP, et al.Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology1999;29:1007. CrossRef

259. PouponRE, LindorKD, ParesA, et al.Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol2003;39:12. CrossRef

260. LindorKD, KowdleyKV, HeathcoteEJ, et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology2004;39:770. CrossRef

261. RatziuV, de LedinghenV, ObertiF, et al.A randomized controlled trial of high‐dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol2011;54:1011. CrossRef

262. RudicJS, PoropatG, KrsticMN, et al.Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev2012;(12):CD000551.

263. ChengK, AshbyD, SmythRL. Ursodeoxycholic acid for cystic fibrosis‐related liver disease. Cochrane Database Syst Rev2012;(10):CD000222.

264. RockeyDC, MaherJJ, JarnaginWR, et al.Inhibition of rat hepatic lipocyte activation in culture by interferon‐gamma. Hepatology1992;16:776. CrossRef

265. RockeyDC, ChungJJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med1994;42:660.

266. MuirAJ, SylvestrePB, RockeyDC. Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat2006;13:322. CrossRef

267. PockrosPJ, JeffersL, AfdhalN, et al.Final results of a double‐blind, placebo‐controlled trial of the antifibrotic efficacy of interferon‐gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology2007;45:569. CrossRef

268. HazraS, XiongS, WangJ, et al.Peroxisome proliferator‐activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem2004;279:11392. CrossRef

269. ShafieiMS, ShettyS, SchererPE, et al.Adiponectin regulation of stellate cell activation via PPARgamma‐dependent and ‐independent mechanisms. Am J Pathol2011;178:2690. CrossRef

270. McHutchisonJ, GoodmanZ, PatelK, et al.Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology2010;138:1365, 73 e1‐2. CrossRef

271. RodriguezL, Cerbon‐AmbrizJ, MunozML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res1998;29:109.

272. KaplanMM, AllingDW, ZimmermanHJ, et al.A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med1986;315:1448. CrossRef

273. KershenobichD, VargasF, Garcia‐TsaoG, et al.Colchicine in the treatment of cirrhosis of the liver. N Engl J Med1988;318:1709. CrossRef

274. MorganTR, WeissDG, NemchauskyB, et al.Colchicine treatment of alcoholic cirrhosis: a randomized, placebo‐controlled clinical trial of patient survival. Gastroenterology2005;128:882. CrossRef

275. RambaldiA, GluudC. Colchicine for alcoholic and non‐alcoholic liver fibrosis or cirrhosis. Liver2001;21:129. CrossRef

276. NovobrantsevaTI, AkincA, BorodovskyA, et al.Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel2008;11:217.

277. VaishnawAK, GollobJ, Gamba‐VitaloC, et al.A status report on RNAi therapeutics. Silence2011;1:14. CrossRef

278. BishtS, KhanMA, BekhitM, et al.A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl4‐induced hepatic injury and fibrosis through reduction of pro‐inflammatory cytokines and stellate cell activation. Lab Invest2011;91:1383. CrossRef

279. van BeugeMM, PrakashJ, LacombeM, et al.Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther2011;337:628. CrossRef

280. IsakaY, BreesDK, IkegayaK, et al.Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med1996;2:418. CrossRef

281. GeorgeJ, RoulotD, KotelianskyVE, et al.In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A1999;96:12719. CrossRef

282. YataY, GotwalsP, KotelianskyV, et al.Dose‐dependent inhibition of hepatic fibrosis in mice by a TGF‐beta soluble receptor: implications for antifibrotic therapy. Hepatology2002;35:1022. CrossRef

283. GonzaloT, BeljaarsL, van de BovenkampM, et al.Local inhibition of liver fibrosis by specific delivery of a platelet‐derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther2007;321:856. CrossRef

284. NicholsonJK, HolmesE, KinrossJ, et al.Host‐gut microbiota metabolic interactions. Science2012;336:1262. CrossRef

285. SekiE, SchnablB. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol2012;590:447. CrossRef

286. SchnablB, BrennerDA. Interactions Between the Intestinal Microbiome and Liver Diseases. Gastroenterology2014.

287. ChassaingB, Etienne‐MesminL, GewirtzAT. Microbiota‐liver axis in hepatic disease. Hepatology2014;59:328. CrossRef

288. Gomez‐HurtadoI, SantacruzA, PeiroG, et al.Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4‐induced fibrosis. PLoS ONE2011;6:e23037. CrossRef

289. DapitoDH, MencinA, GwakGY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell2012;21:504. CrossRef

290. ZhuL, BakerSS, GillC, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology2013;57:601. CrossRef

291. YamaguchiY, TakiharaT, ChambersRA, et al.A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med2012;4:136ra71. CrossRef

292. JiangX, TsitsiouE, HerrickSE, et al.MicroRNAs and the regulation of fibrosis. FEBS J2010;277:2015. CrossRef

293. SekiyaY, OgawaT, YoshizatoK, et al.Suppression of hepatic stellate cell activation by microRNA‐29b. Biochem Biophys Res Commun2011;412:74. CrossRef

294. LaknerAM, SteuerwaldNM, WallingTL, et al.Inhibitory effects of microRNA 19b in hepatic stellate cell‐mediated fibrogenesis. Hepatology2012;56:300. CrossRef

295. Barry‐HamiltonV, SpanglerR, MarshallD, et al.Allosteric inhibition of lysyl oxidase‐like‐2 impedes the development of a pathologic microenvironment. Nat Med2010;16:1009. CrossRef

296. LopezB, GonzalezA, HermidaN, et al.Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol2010;299:H1. CrossRef

297. LiJ, ZhangY, KurubaR, et al.Roles of microRNA‐29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol2011;80:191. CrossRef

298. MudaliarS, HenryRR, SanyalAJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology2013;145:574. CrossRef

299. XuW, HellerbrandC, KohlerUA, et al.The Nrf2 transcription factor protects from toxin‐induced liver injury and fibrosis. Lab Invest2008;88:1068. CrossRef

300. KimIH, KimDG, HaoP, et al.Anti‐fibrotic effects of L‐2‐oxothiazolidine‐4‐carboxylic acid via modulation of nuclear factor erythroid 2‐related factor 2 in rats. BMB Rep2012;45:348. CrossRef

301. ZhaoXY, ZengX, LiXM, et al.Pirfenidone inhibits carbon tetrachloride‐ and albumin complex‐induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol2009;36:963. CrossRef

302. TitosE, ClariaJ, PlanagumaA, et al.Inhibition of 5‐lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J2003;17:1745.

303. KingTEJr, BradfordWZ, Castro‐BernardiniS, et al.A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med2014;370:2083. CrossRef

304. ZeinCO, YerianLM, GogateP, et al.Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo‐controlled trial. Hepatology2011;54:1610. CrossRef

305. Van WagnerLB, KoppeSW, BruntEM, et al.Pentoxifylline for the treatment of non‐alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol2011;10:277.